Specifically, tumor-bearing mice were treated with DB together with control IgG, or neutralizing antibodies for CXCR3 (αCXCR3, 140 μg/mouse) every 4 days or CXCL9 (αCXCL9, 200 μg/mouse) every 3 days, starting 6 days after B16-OVA cell inoculation. Here, CXCL9 is linked to neoplasm.